Ticker

EXEL

Exelixis, Inc.

4 catalysts on file

EXEL

Exelixis, Inc.

PDUFA Confirmed

zanzalintinib

previously treated metastatic colorectal cancer

T-minus 104 days Dec 3, 2026

SEC 8-K verified 2mo ago

Countdown card →

EXEL

Exelixis, Inc.

Phase 2 AI-extracted

zanzalintinib

previously treated metastatic colorectal cancer

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →

EXEL

Exelixis, Inc.

Phase 3 AI-extracted

zanzalintinib

previously treated metastatic colorectal cancer

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →

EXEL

Exelixis, Inc.

Approval AI-extracted

zanzalintinib

previously treated metastatic colorectal cancer

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →